

Research News

April 20, 2020 The Institute of Medical Science The University of Tokyo <u>http://www.ims.u-tokyo.ac.jp/imsut/en/</u>

Understanding the diversity of cancer evolution

based on computational simulation

-Constructing a mathematical basis for developing therapeutic strategies against cancer using a supercomputer-

Understanding the principles of cancer evolution is important in designing a therapeutic strategy. A research group at The Institute of Medical Science, The University of Tokyo (IMSUT) announced a new simulation model that describes various modes of cancer evolution in a unified manner.

"We clarified the conditions under which each of the evolutionary modes is realized by performing simulation analysis using a supercomputer. Our findings have allowed us to explain the underlying principles of the evolutionary diversity of cancer." said lead scientist Atsushi Niida, Senior Assistant Professor, Laboratory of Molecular Medicine, Human Genome Center of IMSUT.

To build a unified evolutionary simulation model

Cancer can be regarded as a disease of evolution, which results from natural selection of cells with high proliferative and malignant potential, following the accumulation of mutations in their genomes. Moreover, because cancer has a high evolutionary potential, it easily adapts to treatment-related changes in its environment and acquires therapeutic resistance (*1),

Previous genomic studies have shown that cancer evolution can be roughly divided into four modes of evolution. However, it has remained unclear what conditions give rise to



each mode. Therefore, the research group have built a unified evolutionary simulation model that can recapitulate a variety of evolutionary modes.

By performing massively parallel simulation(*2) with various conditions on SHIROKANE, a supercomputer at IMSUT, the research group determined the conditions under which each evolution mode is generated. By providing a mathematical basis for understanding cancer evolution, this study is expected to contribute to the understanding of therapeutic resistance in cancer and the development of novel therapeutic strategies.

Various mathematical principles that explain the evolution of cancer

Classically, cancer evolution has been regarded as a process of evolution, in which normal cells evolve step-wise into a homogeneous cell population with high malignancy by serially acquiring driver mutations(*3) that favor cell growth and survival while undergoing natural selection (Figure 1A). However, in recent years, multi-region sequencing(*4), which analyzes DNA samples obtained from multiple regions of a tumor, has demonstrated intratumor heterogeneity (ITH)(*5); that is, multiple clones with different mutations are generated during the course of cancer evolution and coexist in a single tumor. Also, depending on the types of cancers, driver mutations present only in a fraction of cells contribute to ITH; that is, natural selection appears to shape ITH (FIG. 1B).

On the other hand, it has been found that ITH can be shaped by the accumulation of neutral mutations(*6) that do not affect the growth and survival of cells; that is, ITH can be generated by neutral evolution (FIG. 1C). The evolutionary principle underlying ITH has not only varied among cancer types, but Niida and colleagues have also found that a temporal shift occurs during colorectal tumorigenesis (Saito et al., A temporal shift of the evolutionary principle shaping ITH in colorectal cancer, Nature comm., 2018, doi: 10.1038/s41467-018-05226-0); that is, it has been found that, in early lesions, ITH is shaped by natural selection while in advanced cancer, ITH is shaped by neutral evolution. Also, in contrast to the gradual evolution that results from the stepwise accumulation of single nucleotide mutations as assumed above, punctuated evolution has attracted attention. This is an evolutionary mode in which large changes occur over a short time at the chromosomal and genomic levels, such as copy number changes and structural abnormalities, explosively expanding from a few initial cells (Fig. 1D).



Thus far, four evolutionary modes have been proposed, but there are many unclear points concerning under what conditions these modes occur. Simulation using an agent-based model is considered to be a useful tool for understanding the principle of cancer evolution. The agent-based model assumes the components of a system called an agent, and specifies rules for the autonomous behavior of the agent itself and the interactions between agents and the environment.

Viewing each cell as an agent, ITH can be easily represented by the difference in the internal state of each agent. Niida and colleagues have recently developed MASSIVE, a new methodology of parameter sensitivity analysis(*7), which examines the dynamics of agent-based simulations (Niida et al., Sensitivity analysis of agent-based simulation utilizing massively parallel computation and interactive data visualization, PLOS one, 2019, DOI: 10.1371/journal.pone.0210678). MASSIVE takes an approach completely different from conventional parameter sensitivity analysis methods; it makes it possible to intuitively search a large parameter space by combining massively parallel computing with interactive data visualization.

Based on the above, in order to clarify the conditions under which the above-mentioned four different evolution modes are realized, we have constructed a unified evolution simulation model that can recapitulate various evolution modes using an agent-based model. Parameter sensitivity analysis utilizing MASSIVE was performed on SHIROKANE, a supercomputer of IMSUT. They found that linear evolution occurs when strong driver mutations are assumed, while ITH is generated by natural selection when the driver mutations are weak. Moreover, the simulation revealed that the generation of ITH by neutral evolution requires a high neutral mutation rate, and the presence of cancer stem cells also contributes to neutral evolution by promoting the accumulation of neutral mutations.

Punctuated evolution could also be reproduced by assuming an explosive driver gene that enables cells to overcome the resource limitation required for cell proliferation. Furthermore, it was shown by simulation that punctuated evolution triggers the abovedescribed temporal shift of the principle underlying ITH from natural selection to neutral evolution in colorectal tumorigenesis (Fig. 1E). This result also helps us understand that each mode works not as discrete, exclusive modes but rather blend continuously as a series of phases of cancer evolution.



The results of all the simulation analyses in this research can be searched interactively at https://www.hgc.jp/~aniida/canevosim/index.html.



Figure 1 Various modes of cancer evolution

A-D) Four main evolutionary modes in cancer. Red stars represent normal driver mutations such as single nucleotide mutations. A green star represents large-scale genetic alterations at the chromosomal or genomic level that produce copy number or structural abnormalities. E) An evolutionary model that explains the temporal shift of the principle generating ITH during colorectal tumorigenesis.

Contributing toward a deeper understanding of therapeutic resistance in cancer

"In this study, we clarified the principle underlying the diversity of cancer evolution by simulation analysis using a supercomputer. Since cancer has a high evolutionary



potential, it adapts to the environment changed by therapy and easily acquires therapeutic resistance, so understanding the evolutionary principle of cancer is an important problem for designing therapeutic strategies." Niida emphasized

By providing a mathematical basis for understanding cancer evolution, this study is expected to contribute to the understanding of therapeutic resistance in cancer and the development of novel therapeutic strategies.

###

Research Notes

(*1) Therapeutic resistance

A phenomenon in which cancer shows resistance to anti-cancer drug therapies. Even If a tumor in an advanced stage responds to a therapy and temporarily shrinks, it almost always regrows by gaining therapeutic resistance.

(*2) Massively parallel simulation

Preforming thousands of simulations simultaneously on a supercomputer. The computing power of SHIROKANE, the supercomputer used in this study, is several thousand times greater than that of a personal computer.

(*3) Driver mutation

Specific mutations that are thought to cause cancer by working in favor of cell growth and survival. Cells with driver mutations are favored by natural selection and spread within the cell population.

(*4) Sequencing

Determining the sequence of DNA, which encodes genomic information. Usually, in the case of cancer genome sequencing analysis, mutations, which are altered parts in the genome of cancer cells, are identified by comparison to the genome of normal cells from the same individual.

(*5) Intratumor heterogeneity (ITH)

A phenomenon in which multiple types of cell populations with different mutations coexist in a single tumor. It is generated by different cells acquiring different mutations during the evolution of cancer cells.

(*6) Neutral mutation

Mutations that do not affect cell growth or survival. Neutral mutations can spread by chance within a cell population and the phenomenon is called neutral evolution.

(*7) Parameter sensitivity analysis

Determining the conditions that affect the simulation results by repeating the



simulation with altered parameter values that determine the conditions of the simulation model.

About the research

1) Journal Article

Atsushi Niida*, Takanori Hasegawa, Hideki Innan, Tatsuhiro Shibata, Koshi Mimori and Satoru Miyano,2020, "A unified simulation model for understanding the diversity of cancer evolution" *PeerJ.* **DOI:** DOI 10.7717/peerj.8842

Article URL: http://doi.org/10.7717/peerj.8842

2) Publication Journal PeerJ https://peerj.com/

3) Contact

Research Contact

Senior Assistant Professor Atsushi Niida The Institute of Medical Science, The University of Tokyo 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, JAPAN http://www.ims.u-tokyo.ac.jp/imsut/en/

Press Contact

Division for International Affairs office, The Institute of Medical Science, The University of Tokyo

http://www.ims.u-tokyo.ac.jp/imsut/en/

About IMSUT (The Institute of Medical Science, The University of Tokyo)

The Institute of Medical Science, The University of Tokyo (IMSUT) evolved from its origin, the Institute for Infectious Disease in 1967. The mission of IMSUT is to advance basic knowledge underlying infectious diseases, cancer and other intractable diseases and ultimately to control them. IMSUT consists of about 165 faculty members, 224 graduate students coming from various schools such as medicine, science, agriculture, pharmaceutical science, and engineering to develop more effective interdisciplinary research in basic life science and genomic medicine.